FIND: New Software Tool Identifies Population-Enriched Pathogenic Variants in Genetic Databases
Researchers have developed FIND (Founder candidates hidden IN Data), a web-based tool that scans the gnomAD genomic database to identify pathogenic genetic variants enriched in specific ancestry groups. Founder mutations — variants tracing back to a single ancestor and amplified through population bottlenecks and endogamy — are clinically important for targeted disease screening, but many remain undetected in existing datasets. The tool could improve genetic disease detection in historically underrepresented populations, including African American and admixed American groups.
FIND is a freely available web tool designed to surface pathogenic, likely pathogenic, and predicted loss-of-function variants in gnomAD that appear at elevated frequencies in one ancestry group and are at least tenfold more common there than in all other groups. The tool applies a minimum frequency threshold of 0.00008 and zeroes out populations with four or fewer observed alleles to reduce noise. Validation tests on four genes — FLNC, TMEM127, MYH7, and BRCA2 — successfully recovered nine established founder mutations and flagged seven additional candidate founders. Candidate variants enriched in African American and admixed American populations were further cross-validated using the All of Us research database, lending additional support to the tool's findings. The authors emphasize that FIND is particularly valuable for populations historically underrepresented in genetic research, where population-specific disease burdens are poorly characterized. The source code is publicly available on GitHub under an MIT license, and a web interface is accessible without installation.
What's missing
As a preprint posted to bioRxiv, this work has not yet undergone formal peer review, and the clinical validity of the seven newly identified candidate founder mutations has not been independently confirmed. The study does not address the tool's sensitivity and specificity relative to existing founder mutation identification methods. Scalability across all disease genes in gnomAD and potential false-positive rates at the chosen frequency thresholds remain open questions.
What different sources said
- bioRxivCenter
FIND: a software tool for identifying population-enriched pathogenic variants in gnomAD
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.